Inandex (Dexamethasone Phosphate)

Dexamethasone phosphate binds to intracellular glucocorticoid receptors, forming a complex that moves into the cell nucleus. This complex modifies gene transcription, decreasing production of pro‑inflammatory cytokines and limiting immune‑cell activation, which results in potent anti‑inflammatory and immunosuppressive effects.

The specific dose of Inandex is determined by the prescribing clinician based on the indication, severity of disease, patient weight, renal and hepatic function, and route of administration. Healthcare professionals tailor the regimen to achieve optimal therapeutic benefit while minimizing risk.

Safety data for dexamethasone phosphate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Inandex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Inandex delivers dexamethasone phosphate, which is more potent on a milligram‑per‑milligram basis than many other glucocorticoids such as prednisolone. It has a longer duration of action and can be administered via intra‑articular, intramuscular or intravenous routes, offering flexibility for acute and chronic inflammatory conditions.

Inandex should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the product, and avoid shaking the vial. If refrigeration is unavailable for a short period, keep the product in a cool, insulated container and restore proper storage as soon as possible.

Inandex is supplied as a sterile injectable solution and can be given intra‑articularly, intramuscularly or intravenously by a qualified healthcare professional. The route, volume and rate of injection are selected according to the clinical indication and patient’s condition, following aseptic technique.

Serious risks include adrenal suppression, severe infections, gastrointestinal bleeding, osteonecrosis and anaphylaxis. Patients should be monitored for signs of infection, unexplained bruising, persistent abdominal pain, or sudden changes in mood, and clinicians should assess the need for prophylactic measures when using high‑dose or prolonged therapy.

Inandex is contraindicated in patients with known hypersensitivity to dexamethasone or any excipients, those with systemic fungal infections, and individuals receiving live vaccines. Caution is also advised for patients with uncontrolled diabetes, severe hypertension, or active peptic ulcer disease, where alternative therapies may be preferable.